SuperworthIndaptus Therapeutics EPS INDP
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$7.77
- Latest quarter, Q2 FY26
- −$0.02
- Fiscal year 2025
- −$25.72
Indaptus Therapeutics' earnings per share was −$7.77 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.02.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$25.72 | n/a |
| FY2024 | −$45.40 | n/a |
| FY2023 | −$51.80 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | n/a | n/a |
| FY2020 | −$313.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.02 | n/a | −$7.77 | |
| Q1 FY26 | −$0.23 | n/a | −$16.84 | |
| Q4 FY25 | −$4.54 | n/a | −$25.72 | |
| Q3 FY25 | −$2.98 | n/a | −$31.78 | |
| Q2 FY25 | −$9.09 | n/a | −$37.84 | |
| Q1 FY25 | −$9.11 | n/a | −$41.91 | |
| Q4 FY24 | −$10.60 | n/a | −$45.40 | |
| Q3 FY24 | −$9.04 | n/a | −$48.24 | |
| Q2 FY24 | −$13.16 | n/a | −$52.36 | |
| Q1 FY24 | −$12.60 | n/a | −$50.12 | |
| Q4 FY23 | −$13.44 | n/a | −$51.80 | |
| Q3 FY23 | −$13.16 | n/a | −$50.68 |
Against its peers
Companies in Drug Manufacturers - General nearest Indaptus Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INDPIndaptus Therapeutics | −$7.77 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Indaptus Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.